Vinorelbina 50mg/5ml injection
Injection is an anti-cancer medication used in the treatment of breast cancer and non-small cell lung cancer.
Vinorelbine 50 mg/5 mL Injection is an anticancer medicine used to treat certain types of cancer, particularly non-small cell lung cancer (NSCLC). It belongs to the vinca alkaloid class of chemotherapy medicines and works by interfering with the growth and division of cancer cells.
Vinorelbine 50 mg/5 mL Injection contains vinorelbine, an antineoplastic medicine belonging to the vinca alkaloid class. It is supplied as a concentrated solution that must be diluted before intravenous administration.
It is used in cancer treatment, either alone or in combination with other chemotherapy medicines, depending on the type and stage of cancer and the prescribed treatment plan.
Vinorelbine 50 mg/5 mL Injection may be prescribed to:
Treat locally advanced or metastatic non-small cell lung cancer (NSCLC).
Treat metastatic non-small cell lung cancer as a single-agent therapy or in combination with other chemotherapy medicines.
Treat certain cases of metastatic breast cancer, depending on the product's approved indications and local prescribing guidelines.
The appropriate treatment, dose, and combination with other medicines should be determined by an oncologist based on the patient's condition and treatment response.
Vinorelbine works by interfering with microtubules, which are structures that help cells maintain their shape and divide. It binds to tubulin, a protein needed to form microtubules, and prevents their normal development.
This disrupts cell division and stops cancer cells from multiplying, eventually leading to cell death. The treatment response depends on the cancer type, treatment schedule, and individual circumstances.
Take Vinorelbine 50 mg/5 mL Injection exactly as prescribed by your healthcare professional.
This medicine is administered intravenously (into a vein) by a qualified healthcare professional.
The concentrated solution must be diluted using an appropriate infusion solution before administration.
The dose and frequency depend on the cancer type, body surface area, blood counts, liver function, and prescribed chemotherapy regimen.
Treatment may be given alone or alongside other chemotherapy medicines.
Blood tests are generally required before treatment sessions to monitor blood cell counts and assess treatment suitability.
Do not attempt to administer the injection yourself or change the treatment schedule without your oncologist's advice.
The medicine must only be administered intravenously. Leakage into surrounding tissues can cause serious irritation and tissue damage.
Inform your oncologist about your medical history and all medicines, supplements, and herbal products you use before starting treatment.
Use Vinorelbine with particular caution if you have:
Low white blood cell or platelet counts.
Liver disease or impaired liver function.
A history of nerve disorders or peripheral neuropathy.
Severe constipation or a history of bowel obstruction.
Existing respiratory or lung problems.
A history of ischaemic heart disease.
Important medicine interactions:
Strong CYP3A4 inhibitors, including certain antifungal medicines, may increase vinorelbine levels and the risk of side effects.
CYP3A4 inducers, such as rifampicin and phenytoin, may reduce vinorelbine levels.
Other chemotherapy medicines or treatments that suppress bone marrow may increase the risk of low blood cell counts.
Live vaccines may cause complications during treatment because vinorelbine suppresses immune function.
Certain medicines, including itraconazole and ciclosporin, may increase the risk of specific adverse effects.
Regular blood counts and liver function monitoring may be required during treatment. Contact your healthcare team promptly if you develop a fever or signs of infection.
Check all possible medicine interactions with your oncologist or pharmacist before starting any new medicine.
Vinorelbine can cause harm to an unborn baby and is generally contraindicated during pregnancy. Women who could become pregnant should use effective contraception during treatment and for the period recommended by their oncologist after the final dose.
Breastfeeding should be discontinued before starting treatment because the medicine may pose a risk to the nursing infant.
Both men and women should discuss fertility preservation and contraception with their healthcare professional before beginning treatment, as vinorelbine may affect reproductive function.
Like all medicines, Vinorelbine 50 mg/5 mL Injection can cause side effects, although not everyone experiences them.
Common side effects may include:
Nausea and vomiting.
Constipation.
Fatigue or weakness.
Anaemia (low red blood cell count).
Neutropenia (low neutrophil count).
Hair loss.
Peripheral neuropathy, which may cause tingling or numbness.
Injection-site reactions.
Seek prompt medical attention if you develop fever, chills, signs of infection, severe constipation or abdominal pain, unusual bleeding, difficulty breathing, or severe allergic reactions. Vinorelbine can cause significant bone marrow suppression, which may lead to serious infections.
This is not a complete list of side effects or warnings. Please refer to the product packaging and patient information leaflet supplied with your medicine for complete information and speak with your doctor or pharmacist if you have concerns.
Store Vinorelbine 50 mg/5 mL Injection according to the instructions shown on the original product packaging.
Keep the injection in its original packaging.
Protect it from direct light.
Do not freeze the medicine.
Follow the manufacturer's specified refrigeration requirements.
Keep out of reach of children.
Do not use the injection after its expiry date.
Storage conditions may vary depending on the manufacturer and product presentation. Some vinorelbine products require refrigeration between 2°C and 8°C.
Vinorelbine is a chemotherapy medicine used to treat certain cancers, particularly non-small cell lung cancer. Depending on the product's approved indications, it may also be used for certain cases of metastatic breast cancer.
Vinorelbine interferes with microtubule formation, which cancer cells need to divide and multiply. By disrupting cell division, it helps prevent cancer cells from growing.
It is administered directly into a vein by a qualified healthcare professional. The concentrated solution must be diluted before intravenous administration.
The treatment schedule depends on the cancer type, prescribed chemotherapy combination, and individual treatment plan. It is commonly administered on a weekly schedule, but the oncologist determines the appropriate frequency.
Yes. Vinorelbine may be prescribed alone or in combination with other chemotherapy medicines, such as cisplatin, depending on the treatment protocol. The combination and dosage must be determined by an oncologist.
Hair loss can occur during treatment, although the extent varies between individuals. Other side effects, such as nausea, constipation, fatigue, and changes in blood cell counts, may also occur.
Contact your oncology team promptly if you develop a fever or signs of infection. Vinorelbine can lower white blood cell counts, increasing the risk of serious infections.